...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: AACR 2018
2
Jan 18, 2018 04:07PM
5
Feb 21, 2018 11:38AM
3
Feb 21, 2018 05:45PM
4
Feb 21, 2018 05:52PM
5
Feb 22, 2018 10:34AM
4
Feb 22, 2018 02:25PM
3
Feb 23, 2018 02:54AM
3
Feb 23, 2018 11:14AM
3
Feb 23, 2018 12:41PM
3
Feb 27, 2018 06:33PM
1
Feb 27, 2018 08:43PM
4
Feb 28, 2018 10:42AM
2
Feb 28, 2018 05:41PM
3
Feb 28, 2018 05:57PM
2
Mar 01, 2018 05:17PM
2
Mar 01, 2018 09:35PM
1
Mar 05, 2018 03:13PM
2
Mar 05, 2018 03:59PM
2
Mar 05, 2018 11:08PM

Toinv - Zenith gets up to date information each week on the patients in each leg of the trial according to a side conversation at the AGM in Dec. 

BDAZ - Fortunately or unfortunately they are a private company and can hold onto any information for as long as they see fit. They can also disclose that information to any party they choose, under ca agreement for marketing or any other purpose. Same goes for potential investors.

Not having to disclose any scientific results could be beneficial in their sale strategy, or not.

tada

2
Mar 06, 2018 10:13AM
2
Mar 06, 2018 01:15PM
2
Mar 06, 2018 01:24PM
2
Mar 21, 2018 11:36AM
3
Apr 13, 2018 09:23AM
Share
New Message
Please login to post a reply